Abstract:
Objective To analyze the 5-year survival status of cancer patients registered on a hospital-based cancer registry database in 2019, thereby providing regional evidence for cancer prevention and therapy based on real-world data.
Methods A total of 28,111 patients diagnosed with malignant tumors and received inpatient treatment at the Tianjin Medical University Cancer Institute & Hospital between January and December 2019, were retrospectively followed. Endpoint data were collected through telephone follow-ups, medical record reviews, and death registry data linkages. The final follow-up date was August 2025. The overall survival (OS) rate was estimated using the Kaplan-Meier method. Subgroup analyses were performed according to cancer type, sex, and age group, and differences between survival curves were examined using the Log-rank test.
Results The top three cancer types were breast (7,246 cases), thyroid (5,527 cases), and lung cancers (4,898 cases). The 1-, 3-, and 5-year OS rates for all malignant tumors were 92.5%, 83.6%, and 78.7%, respectively. The 5-year OS rates varied substantially among the various cancer types, with those for thyroid, breast, and uterine corpus cancers exceeding 90.0% and that for pancreatic cancer being only 20.8%. According to the subgroup analyses, female patients had better survival outcomes than those of the male patients and the OS rate declined with increasing age.
Conclusions More than 70% of patients in this cohort survived beyond 5 years after receiving standard diagnosis and treatment. Moreover, survival outcomes varied significantly across cancer types, age groups, and sexes. Therefore, greater attention should be paid to priority cancer types, male patients, and older populations to further improve prognoses and reduce the burden of malignant tumors.
下载: